Veradigm Inc. (MDRX)
| Previous Close | 7.55 |
| Open | 7.50 |
| Bid | 0.00 x 2900 |
| Ask | 0.00 x 1000 |
| Day's Range | 7.47 - 7.70 |
| 52 Week Range | 5.01 - 14.09 |
| Volume | |
| Avg. Volume | 4,508,917 |
| Market Cap | 812.682M |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | 8.78 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Oct 07, 2008 |
| 1y Target Est | N/A |
- Business Wire
Veradigm Network Solution Practice Fusion EHR Receives Top Ambulatory Rankings
CHICAGO, April 09, 2024--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Practice Fusion first for Ambulatory EHR PM Family Practice and Ambulatory EHR PM Primary Care General Practice within its 2024 Top Client/User-Rated Electronic Health Records & Practice Management Solutions report.
- Business Wire
Veradigm to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
CHICAGO, March 14, 2024--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions announced today that Dr. Yin Ho, Veradigm Interim Chief Executive Officer and board member, Lee Westerfield, Interim Chief Financial Officer, and Will Manidis Co-Founder of ScienceIO will participate in a fireside chat at the KeyBanc Capital Markets Life Science & MedTech Investor Forum on Tuesday, March 19th, 2024 at 12:00 PM EDT.
- Business Wire
Veradigm Announces Initial Financial Guidance for Fiscal 2024
CHICAGO, March 13, 2024--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today it has reaffirmed the estimated, unaudited ranges for fiscal 2023 of GAAP Revenue, Adjusted EBITDA, and Non-GAAP diluted earnings per share that it provided on January 10, 2024, in the Company’s Form 8-K filed on January 10, 2024, and initially reaffirmed on February 27, 2024.
